CN105377252A - 利用天然化合物和/或饮食调控癌症 - Google Patents

利用天然化合物和/或饮食调控癌症 Download PDF

Info

Publication number
CN105377252A
CN105377252A CN201480028215.2A CN201480028215A CN105377252A CN 105377252 A CN105377252 A CN 105377252A CN 201480028215 A CN201480028215 A CN 201480028215A CN 105377252 A CN105377252 A CN 105377252A
Authority
CN
China
Prior art keywords
compositions
cancer
tumor
carcinoma
experimenter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480028215.2A
Other languages
English (en)
Chinese (zh)
Inventor
B·雷诺兹
L·德莱罗尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Priority to CN201910619212.0A priority Critical patent/CN110420329A/zh
Publication of CN105377252A publication Critical patent/CN105377252A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/055—Organic compounds containing sulfur as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
CN201480028215.2A 2013-03-14 2014-03-12 利用天然化合物和/或饮食调控癌症 Pending CN105377252A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910619212.0A CN110420329A (zh) 2013-03-14 2014-03-12 利用天然化合物和/或饮食调控癌症

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784386P 2013-03-14 2013-03-14
US61/784,386 2013-03-14
PCT/US2014/023934 WO2014159500A1 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910619212.0A Division CN110420329A (zh) 2013-03-14 2014-03-12 利用天然化合物和/或饮食调控癌症

Publications (1)

Publication Number Publication Date
CN105377252A true CN105377252A (zh) 2016-03-02

Family

ID=51625178

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480028215.2A Pending CN105377252A (zh) 2013-03-14 2014-03-12 利用天然化合物和/或饮食调控癌症
CN201910619212.0A Pending CN110420329A (zh) 2013-03-14 2014-03-12 利用天然化合物和/或饮食调控癌症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910619212.0A Pending CN110420329A (zh) 2013-03-14 2014-03-12 利用天然化合物和/或饮食调控癌症

Country Status (9)

Country Link
US (2) US20160038456A1 (enExample)
EP (1) EP2968260B1 (enExample)
JP (2) JP6488276B2 (enExample)
CN (2) CN105377252A (enExample)
AU (3) AU2014240467B2 (enExample)
BR (1) BR112015023190A2 (enExample)
CA (1) CA2912518A1 (enExample)
IN (1) IN2015DE09621A (enExample)
WO (1) WO2014159500A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108192866A (zh) * 2018-03-07 2018-06-22 郑州大学第附属医院 Sfn联合il-15和il-21制备记忆性t细胞的方法及应用
CN110420178A (zh) * 2019-09-11 2019-11-08 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) * 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および／または規定食を用いた炎症の治療方法
JP7120564B2 (ja) * 2015-09-04 2022-08-17 国立大学法人大阪大学 癌における食事療法の開発
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
EP3861992B1 (en) * 2020-02-07 2023-09-06 CannaFamily a.s. Combination therapy comprising plant derived compounds and antineoplastic compounds for treatment of hematological malignancies
PL4190173T3 (pl) * 2020-09-23 2025-01-07 Aminovita S.L. Metaboliczna terapia przeciwnowotworowa
TW202339712A (zh) * 2022-01-24 2023-10-16 國立大學法人大阪大學 用於治療癌症之組合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304724A (zh) * 2001-01-19 2001-07-25 郭兴华 一种防治骨质疏松、癌症和降血脂组合物及其应用
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
WO2012092916A1 (de) * 2011-01-06 2012-07-12 Johannes Coy Schokoladenmasse

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725895B1 (en) * 1995-09-15 2000-10-10 Hopkins J School Of Medicine Method of preparing food product from cruciferous seeds
US6242018B1 (en) * 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
JPH1149793A (ja) * 1997-08-08 1999-02-23 Momoya:Kk 野菜由来の抗腫瘍性物質
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
JP2007153834A (ja) * 2005-12-07 2007-06-21 Univ Kansai カイワレ大根由来の不凍活性を有する抽出物、その製造方法、ならびにその用途
EP2205237A1 (en) 2007-10-16 2010-07-14 Johns Hopkins University Methods for protecting the skin from radiation insults
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
DE102011008017A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Erfrischungsgetränk
WO2012113415A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
CA2831403A1 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
GB201210699D0 (en) 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
EP2849737B1 (en) 2012-07-05 2019-09-11 Nutramax Laboratories, Inc. Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US20140275235A1 (en) 2013-03-15 2014-09-18 Loic Pierre Deleyrolle Treatment of Proliferative Disorders
WO2014168736A1 (en) 2013-03-15 2014-10-16 Nutramax Laboratories, Inc. Sulforaphane/sulforaphane precursor and phytosterol/phytostanol compositions
MY180761A (en) 2013-03-19 2020-12-08 Univ South Florida Compositions and methods for producing elevated and sustained ketosis
PL2996704T3 (pl) 2013-05-14 2021-06-28 Mars, Incorporated Kompozycja do ochrony stawów
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
WO2015034812A2 (en) 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
JP2018518513A (ja) 2015-06-26 2018-07-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 天然の化合物および／または規定食を用いた炎症の治療方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304724A (zh) * 2001-01-19 2001-07-25 郭兴华 一种防治骨质疏松、癌症和降血脂组合物及其应用
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
WO2012092916A1 (de) * 2011-01-06 2012-07-12 Johannes Coy Schokoladenmasse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
金彪等: "《白萝卜的养生智慧》", 30 November 2010 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108192866A (zh) * 2018-03-07 2018-06-22 郑州大学第附属医院 Sfn联合il-15和il-21制备记忆性t细胞的方法及应用
CN110420178A (zh) * 2019-09-11 2019-11-08 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法
CN110420178B (zh) * 2019-09-11 2022-08-05 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法

Also Published As

Publication number Publication date
EP2968260A1 (en) 2016-01-20
EP2968260B1 (en) 2020-12-16
JP2016514135A (ja) 2016-05-19
AU2020223647A1 (en) 2020-09-10
US20160038456A1 (en) 2016-02-11
AU2019201369A1 (en) 2019-03-21
AU2014240467B2 (en) 2018-11-29
JP2018162248A (ja) 2018-10-18
BR112015023190A2 (pt) 2017-07-18
JP6488276B2 (ja) 2019-03-20
IN2015DE09621A (en) 2016-02-26
US11666549B2 (en) 2023-06-06
CA2912518A1 (en) 2014-10-02
US20210008024A1 (en) 2021-01-14
AU2014240467A1 (en) 2015-11-05
WO2014159500A1 (en) 2014-10-02
CN110420329A (zh) 2019-11-08
EP2968260A4 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
US11666549B2 (en) Regulation of cancer using natural compounds and/or diet
JP6870046B2 (ja) 癌治療
US11020372B2 (en) Dietary and natural product management of negative side effects of cancer treatment
Shen et al. Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma
JP6090836B2 (ja) 化学療法剤の抗腫瘍活性増強剤
JP7673993B2 (ja) 癌の転移抑制および治療用組成物
US20160220627A1 (en) Extracts of curcuma amada and uses thereof
US20230165832A1 (en) Compositions and methods for treating cancer with andrographolide and melatonin combination therapy
WO2020199973A1 (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
US9546354B2 (en) Z cells activated by zinc finger-like protein and uses thereof in cancer treatment
KR101613005B1 (ko) 항암제에 의해 유발되는 신장 독성 질환의 예방 및 치료용 약학적 조성물
TORI HUDSON “Dr. Stengler and Dr. Anderson expertly provide clear, practical tools that can possibly save your life or someone close to you. By harnessing the healing power of nature, Outside the Box Cancer Therapies gives the answers to beating cancer naturally.”—MICHAEL T. MURRAY, ND
JP2010083848A (ja) アンチエージング剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160302